KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Price, Quote, News and Overview
NASDAQ:KZIA - Nasdaq - US48669G3039 - ADR - Currency: USD
KZIA Quote, Performance and Key Statistics
NASDAQ:KZIA (7/3/2025, 12:34:27 PM)
6.63
+0.05 (+0.76%)
The current stock price of KZIA is 6.63 USD. In the past month the price increased by 37.37%. In the past year, price decreased by -34.4%.
KZIA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.5 | 335.62B | ||
| AMGN | AMGEN INC | 14.38 | 160.57B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 138.90B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.4 | 59.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.12B | ||
| ARGX | ARGENX SE - ADR | 94.53 | 33.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.27 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.39B | ||
| NTRA | NATERA INC | N/A | 22.02B | ||
| BIIB | BIOGEN INC | 8.37 | 19.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.29B |
Related stock screener links
About KZIA
Company Profile
Kazia Therapeutics Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Sydney, New South Wales. Kazia Therapeutics Limited is an oncology-focused drug development company. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Company Info
KAZIA THERAPEUTICS-SPON ADR
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney NEW SOUTH WALES 2000 AU
CEO: James Garner
Employees: 13
Phone: 1161298780088
KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ
What is the stock price of KAZIA THERAPEUTICS-SPON ADR today?
The current stock price of KZIA is 6.63 USD. The price increased by 0.76% in the last trading session.
What is the ticker symbol for KAZIA THERAPEUTICS-SPON ADR stock?
The exchange symbol of KAZIA THERAPEUTICS-SPON ADR is KZIA and it is listed on the Nasdaq exchange.
On which exchange is KZIA stock listed?
KZIA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KAZIA THERAPEUTICS-SPON ADR stock?
7 analysts have analysed KZIA and the average price target is 56.36 USD. This implies a price increase of 750% is expected in the next year compared to the current price of 6.63. Check the KAZIA THERAPEUTICS-SPON ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KAZIA THERAPEUTICS-SPON ADR worth?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a market capitalization of 37.06M USD. This makes KZIA a Nano Cap stock.
How many employees does KAZIA THERAPEUTICS-SPON ADR have?
KAZIA THERAPEUTICS-SPON ADR (KZIA) currently has 13 employees.
What are the support and resistance levels for KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a support level at 6.11 and a resistance level at 6.34. Check the full technical report for a detailed analysis of KZIA support and resistance levels.
Is KAZIA THERAPEUTICS-SPON ADR (KZIA) expected to grow?
The Revenue of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the KZIA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KZIA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KZIA, evaluating the profitability, health, valuation and growth aspects
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Sales and EPS estimates to see what analysts future expectations are.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Chart to make your own analysis
- KAZIA THERAPEUTICS-SPON ADR (KZIA) Latest news and press-releases to stay up to date.
Does KAZIA THERAPEUTICS-SPON ADR (KZIA) stock pay dividends?
KZIA does not pay a dividend.
What is the Price/Earnings (PE) ratio of KAZIA THERAPEUTICS-SPON ADR (KZIA)?
KAZIA THERAPEUTICS-SPON ADR (KZIA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.35).
What is the Short Interest ratio of KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?
The outstanding short interest for KAZIA THERAPEUTICS-SPON ADR (KZIA) is 17.53% of its float. Check the ownership tab for more information on the KZIA short interest.
KZIA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to KZIA. When comparing the yearly performance of all stocks, KZIA is one of the better performing stocks in the market, outperforming 79.48% of all stocks.
KZIA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KZIA. KZIA may be in some trouble as it scores bad on both profitability and health.
KZIA Financial Highlights
Over the last trailing twelve months KZIA reported a non-GAAP Earnings per Share(EPS) of -3.35. The EPS increased by 92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KZIA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KZIA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -236463.64% and a revenue growth -100% for KZIA